FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2775284833> ?p ?o ?g. }

• W2775284833 abstract "Accumulating evidence demonstrates that the Urokinase Receptor (uPAR) regulates tumor cell migration through its assembly in composite regulatory units with transmembrane receptors, and uPAR88-92 is the minimal sequence required to induce cell motility through the Formyl Peptide Receptor type 1 (FPR1). Both uPAR and FPR1 are involved in melanoma tumor progression, suggesting that they may be targeted for therapeutic purposes. In this study, the role of the uPAR-FPR1 cross-talk to sustain melanoma cell ability to invade extracellular matrix and cross endothelial barriers is investigated. Also, the possibility that inhibition of the uPAR mediated FPR1-dependent signaling may prevent matrix invasion and transendothelial migration of melanoma cells was investigated.Expression levels of uPAR and FPR1 were assessed by immunocytochemistry, Western Blot and qRT-PCR. Cell migration was investigated by Boyden chamber and wound-healing assays. Migration and invasion kinetics, trans-endothelial migration and proliferation of melanoma cells were monitored in real time using the xCELLigence technology. The agonist-triggered FPR1 internalization was visualized by confocal microscope. Cell adhesion to endothelium was determined by fluorometer measurement of cell-associated fluorescence or identified on multiple z-series by laser confocal microscopy. The 3D-organotypic models were set up by seeding melanoma cells onto collagen I matrices embedded dermal fibroblasts. Data were analyzed by one-way ANOVA and post-hoc Dunnett t-test for multiple comparisons.We found that the co-expression of uPAR and FPR1 confers to A375 and M14 melanoma cells a clear-cut capability to move towards chemotactic gradients, to cross extracellular matrix and endothelial monolayers. FPR1 activity is required, as cell migration and invasion were abrogated by receptor desensitization. Finally, melanoma cell ability to move toward chemotactic gradients, invade matrigel or fibroblast-embedded collagen matrices and cross endothelial monolayers are prevented by anti-uPAR84-95 antibodies or by the RI-3 peptide which we have previously shown to inhibit the uPAR84-95/FPR1 interaction.Collectively, our findings identify uPAR and FPR1 as relevant effectors of melanoma cell invasiveness and suggest that inhibitors of the uPAR84-95/FPR1 cross-talk may be useful for the treatment of metastatic melanoma." @default.
• W2775284833 created "2017-12-22" @default.
• W2775284833 creator A5006977348 @default.
• W2775284833 creator A5015675599 @default.
• W2775284833 creator A5016262549 @default.
• W2775284833 creator A5023150524 @default.
• W2775284833 creator A5029398339 @default.
• W2775284833 creator A5049997641 @default.
• W2775284833 creator A5052593572 @default.
• W2775284833 creator A5066163177 @default.
• W2775284833 creator A5067026848 @default.
• W2775284833 creator A5083575894 @default.
• W2775284833 creator A5087279958 @default.
• W2775284833 date "2017-12-01" @default.
• W2775284833 modified "2023-10-12" @default.
• W2775284833 title "Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells" @default.
• W2775284833 cites W1527111349 @default.
• W2775284833 cites W1555312557 @default.
• W2775284833 cites W1569704448 @default.
• W2775284833 cites W1572567571 @default.
• W2775284833 cites W1634520049 @default.
• W2775284833 cites W1712302576 @default.
• W2775284833 cites W1732043081 @default.
• W2775284833 cites W1909089874 @default.
• W2775284833 cites W1968783143 @default.
• W2775284833 cites W1975227860 @default.
• W2775284833 cites W1976767579 @default.
• W2775284833 cites W1982968895 @default.
• W2775284833 cites W1985450903 @default.
• W2775284833 cites W1992974034 @default.
• W2775284833 cites W1994916125 @default.
• W2775284833 cites W2008318585 @default.
• W2775284833 cites W2009275201 @default.
• W2775284833 cites W2009927285 @default.
• W2775284833 cites W2012080977 @default.
• W2775284833 cites W2015880778 @default.
• W2775284833 cites W2022349358 @default.
• W2775284833 cites W2029160993 @default.
• W2775284833 cites W2044857500 @default.
• W2775284833 cites W2051823623 @default.
• W2775284833 cites W2059311738 @default.
• W2775284833 cites W2059546857 @default.
• W2775284833 cites W2064283575 @default.
• W2775284833 cites W2064911312 @default.
• W2775284833 cites W2073864312 @default.
• W2775284833 cites W2079168625 @default.
• W2775284833 cites W2082908557 @default.
• W2775284833 cites W2083707515 @default.
• W2775284833 cites W2086864815 @default.
• W2775284833 cites W2096812369 @default.
• W2775284833 cites W2103896403 @default.
• W2775284833 cites W2105029855 @default.
• W2775284833 cites W2105660237 @default.
• W2775284833 cites W2109723860 @default.
• W2775284833 cites W2123657616 @default.
• W2775284833 cites W2126749305 @default.
• W2775284833 cites W2129986286 @default.
• W2775284833 cites W2131040858 @default.
• W2775284833 cites W2131307163 @default.
• W2775284833 cites W2131896212 @default.
• W2775284833 cites W2132867241 @default.
• W2775284833 cites W2134468750 @default.
• W2775284833 cites W2137415963 @default.
• W2775284833 cites W2140690574 @default.
• W2775284833 cites W2140859605 @default.
• W2775284833 cites W2152000742 @default.
• W2775284833 cites W2155199341 @default.
• W2775284833 cites W2159316810 @default.
• W2775284833 cites W2165437268 @default.
• W2775284833 cites W2169917705 @default.
• W2775284833 cites W2169961966 @default.
• W2775284833 cites W2210081271 @default.
• W2775284833 cites W2219978888 @default.
• W2775284833 cites W2331665234 @default.
• W2775284833 cites W2337731566 @default.
• W2775284833 cites W2425871195 @default.
• W2775284833 cites W2487318770 @default.
• W2775284833 cites W2605233023 @default.
• W2775284833 cites W2607866982 @default.
• W2775284833 cites W4211002554 @default.
• W2775284833 doi "https://doi.org/10.1186/s13046-017-0650-x" @default.
• W2775284833 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5721612" @default.
• W2775284833 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29216889" @default.
• W2775284833 hasPublicationYear "2017" @default.
• W2775284833 type Work @default.
• W2775284833 sameAs 2775284833 @default.
• W2775284833 citedByCount "16" @default.
• W2775284833 countsByYear W27752848332018 @default.
• W2775284833 countsByYear W27752848332019 @default.
• W2775284833 countsByYear W27752848332020 @default.
• W2775284833 countsByYear W27752848332021 @default.
• W2775284833 countsByYear W27752848332022 @default.
• W2775284833 crossrefType "journal-article" @default.
• W2775284833 hasAuthorship W2775284833A5006977348 @default.
• W2775284833 hasAuthorship W2775284833A5015675599 @default.
• W2775284833 hasAuthorship W2775284833A5016262549 @default.
• W2775284833 hasAuthorship W2775284833A5023150524 @default.
• W2775284833 hasAuthorship W2775284833A5029398339 @default.
• W2775284833 hasAuthorship W2775284833A5049997641 @default.
• W2775284833 hasAuthorship W2775284833A5052593572 @default.

• next